Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 19, 2023PharmaceuticalsOpen Access

Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

SMSonia MorèMarche Polytechnic UniversityLCLaura CorvattaOspedale di SpoletoVMValentina Maria ManieriMarche Polytechnic University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Morè et al. (2023) studied this question.

synapsesocial.com/papers/6a0ffaf32badbc352aff1484https://doi.org/10.3390/ph16111628
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies2015 · 132 citations
  2. 2Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing2017 · 305 citations
  3. 3Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions2017 · 44 citations
  4. 4Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma2014 · 490 citations
  5. 5Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).2023 · 94 citations